AxoGen (AXGN) Akcija Kursas
AxoGen Kursas
Pajamos augo 48,3 % per metus per pastaruosius 19 metus iki 225,21 mln. USD. AxoGen grynoji marža dabar yra −7,0 %, išaugo nuo −21,2 % prieš kelerius metus. AxoGen šiuo metu siūlo apie 2,81 % dividendo pajamingumą. Analitikų tikslinės kainos mediana yra 51,50 USD, t. y. virš dabartinę kainą 44,5 %. Iš 16 analitikų 15 rekomenduoja pirkti — bendras konsensusas yra Pirkti.
AxoGen akcijos kaina
Gaukite šiuos duomenis per Eulerpool API
100 000 užklausų/mėn. nemokamai · be kortelės
AxoGen akcija ir akcijų analizė
Dažnai užduodami klausimai apie AxoGen akciją
AxoGen Inc is a leading medical technology company focused on the development and commercialization of innovative solutions for peripheral nerve injuries. Their business model revolves around providing advanced surgical solutions to patients suffering from nerve damage. AxoGen offers a comprehensive portfolio of products and services that support nerve repair and regeneration, enabling patients to regain function and improve their quality of life. Through their cutting-edge technologies, AxoGen aims to revolutionize the field of peripheral nerve repair, bringing hope and relief to individuals with nerve injuries.
AxoGen Inc is primarily active in the healthcare industry.
The main competitors of AxoGen Inc in the market include Integra LifeSciences Holdings Corporation, Baxter International Inc., Stryker Corporation, and Medtronic plc.
AxoGen Inc. is a biotechnology company specializing in the development and commercialization of innovative surgical solutions for peripheral nerve injuries. Founded in 2002, AxoGen is headquartered in Alachua, Florida, and operates globally. The company is dedicated to advancing the science and understanding of nerve injury and regeneration through its proprietary Avance® Nerve Graft and AxoGuard® Nerve Protector products. With an experienced management team, AxoGen continues to drive innovation in nerve repair and restoration, providing hope and improved outcomes for patients suffering from nerve damage. AxoGen Inc. has established itself as a leader in the field, offering groundbreaking solutions to healthcare providers and patients worldwide.
AxoGen Inc has achieved several significant milestones throughout its history. The company has successfully developed and commercialized innovative nerve repair technology, making it a leader in the field. AxoGen has achieved FDA clearance and European CE mark approval for its products. It has also expanded its market presence by establishing distribution agreements with leading healthcare providers globally. AxoGen has consistently demonstrated strong financial performance, with increased revenues and record-breaking sales. The company's commitment to research and development has led to numerous patents and the introduction of groundbreaking surgical solutions. Overall, AxoGen Inc has made remarkable progress in transforming the field of nerve repair and continues to pave the way for future advancements.
AxoGen Inc is primarily present in the United States.
AxoGen Inc represents the values of innovation, collaboration, and patient-centricity. As a leading company in the field of nerve repair and regeneration, AxoGen is dedicated to developing and providing innovative solutions for patients with peripheral nerve injuries. Their corporate philosophy revolves around improving patient outcomes and enhancing the quality of life by delivering safe and effective treatments. By prioritizing collaboration with healthcare professionals and researchers, AxoGen ensures that their products are developed with the latest scientific advancements. With an unwavering commitment to patient well-being, AxoGen continues to make significant contributions to the field of nerve repair.
Analitikai šiuo metu nustato vidutinę AxoGen akcijos tikslinę kainą 50,17 USD (mediana: 51,50 USD), t. y. +40,8 % palyginti su paskutine kaina. Konsensusas pagrįstas 16 analitikų reitingais.
16 analitikai šiuo metu vertina AxoGen akciją: 15 rekomenduoja pirkti, 1 laikyti ir 0 parduoti. 2026 m. analitikai tikisi, kad AxoGen gaus 282,57 mln. USD pajamų ir 0,44 USD pelno akcijai.
Pagal dabartinį kursą AxoGen akcija kainuoja 31,77 EUR (35,63 USD).
AxoGen akcija (AXGN) kotiruojama 4 biržose, įskaitant: NASDAQ (AXGN), London (0HKD.L), Frankfurt (LT3.F).
AxoGen Inc is a medical device company specializing in the development, manufacturing, and marketing of nerve repair products. The company, founded in 2002 in Florida, USA, aims to help improve patients' quality of life and alleviate pain and impairments caused by damages to peripheral nerves. They offer a range of products tailored to the specific needs of patients with nerve injuries, including the AxoGuard® Nerve Protector, biologics, regenerative medicine, neurostimulation, and the AxoTouch Test. The AxoGuard® Nerve Protector is designed to prevent damage to peripheral nerves and consists of breathable, implantable sleeves that provide protection. It is typically used to protect or repair nerves after surgery or due to injuries. Biologics, another branch of AxoGen Inc, involves the use of biological materials to accelerate the healing process of injured nerves, such as stem cells, Botulinum toxin injection, and antibodies to promote repair. Regenerative medicine products utilize regenerative forces to accelerate healing and promote the formation of new tissue, with Avance® Nerve Graft being the flagship product made from frozen human nerves processed mechanically and enzymatically to obtain a highly pure and biocompatible product. Neurostimulation focuses on the use of electronic devices to stimulate the nervous system, helping to alleviate pain and expedite healing. AxoStim® electrostimulation systems are among the products in this field. The AxoTouch Test is a diagnostic tool used to diagnose nerve damage, measuring pressure and touch sensitivity in the patient's body. It consists of a handheld instrument, a touch sensitivity measurement device, and specialized software packages for data analysis. AxoGen Inc's business model revolves around providing products for nerve damage regeneration, offering a comprehensive range of products tailored to patients' specific needs. The company is dedicated to developing innovative technologies and products to enhance the lives of individuals suffering from nerve damage and associated pain and impairments.
tikėtina pelnas AxoGen yra 282,57 mln. USD. Šis skaičius grindžiamas dabartiniais finansiniais duomenimis ir atspindi įmonės verslo rezultatus.
tikėtina grynasis pelnas AxoGen yra 20,62 mln. USD. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.
Kainų ir nuomos santykis (KGV) AxoGen šiuo metu yra 81,11. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti AxoGen akcijos vertę.
Kainų ir pardavimų santykis (KUV) AxoGen šiuo metu yra 5,92. KUV lygina rinkos kapitalizaciją su metinėmis pajamomis ir yra AxoGen akcijos įvertinimo metrika.
Eulerpool kokybės balas AxoGen yra 4/10.
AxoGen ISIN yra US05463X1063. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.
AxoGen WKN yra A1JMHK. WKN (Wertpapierkennnummer) yra šešiaženklė vokiška vertybinių popierių identifikacijos sistema.
AxoGen prekybos žymė yra AXGN. Ši biržos žymė naudojama AxoGen akcijoms prekiauti biržoje.
AxoGen akcija
AxoGen Pagrindiniai konkurentai
AxoGen Biržos simbolis
AxoGen FIGI
Visos AxoGen pagrindinės charakteristikos ir giluminė analizė
Mūsų akcijų analizė AxoGen akcijai apima svarbius finansinius rodiklius, tokius kaip apyvarta, pelnas, P/E santykis, P/S santykis, EBIT, taip pat informaciją apie dividendes. Be to, mes nagrinėjame aspektus, tokius kaip akcijos, rinkos kapitalizacija, skolos, nuosavas kapitalas ir įsipareigojimai AxoGen. Jei ieškote išsamesnės informacijos šiais klausimais, mūsų poskyriuose galite rasti išsamias analizes: